Tatva Chintan Pharma Chem Ltd.

NSE: TATVA | BSE: 543321 | ISIN: INE0GK401011 |Industry: Specialty Chemicals
|
2478.50 122.85 (5.22%)
NSE Dec 01, 2021 15:31 PM
Volume: 128.5K
 

2478.50
5.22%

Highlights:

  • Revenue from Operations for the quarter was Rs 1,236.15 million higher by 106%
  • EBITDA for the quarter was Rs 386.98 million higher by 365%
  • EBIDTA Margin for the quarter was at 31.31% higher by 1,746 bps
  • Net Profit for the quarter was Rs 324.12 million higher by 811%
  • Net Profit Margin for the quarter was at 25.64% higher by 1990 bps
  • Basic and Diluted EPS for the quarter was Rs 15.02 per share, increased by 749% 

    Results at Glance (Y-O-Y – 1H FY22 COMPARED WITH 1H FY21) 
     
  • Revenue from Operations for the half year was Rs 2,304.47 million higher by 107%
  • EBITDA for the half year was Rs 662.96 million higher by 242%
  • EBIDTA Margin for the half year was at 28.77% higher by 1,138 bps
  • Net Profit for the half year was Rs 555.58 million higher by 441%
  • Net Profit Margin for the half year was at 23.64% higher by 1,466 bps
  • Basic and Diluted EPS for the half year was Rs 26.7 per share, increased by 422% 
     

Commenting on the Q2 & H1 performance Mr. Chintan Shah, Managing Director, said, as we have announced our results just before Diwali; I take this opportunity to wish each one of you a very Happy Diwali and Prosperous New year, let us hope we all have a wonderful, successful & most importantly a healthy year ahead. 

I am pleased to inform you that we have reported a historically record-breaking performance in 2QFY22; we are very well on our way of being recognized as a niche player in the speciality chemical space with our focus on manufacturing Phase Transfer Catalyst, Structure Directing Agents, Electrolyte Salts, Pharma & Agrochemical Intermediates and Speciality Chemicals. We have a clear focus on adopting green chemistry processes supported by our state-of-the-art research and development facility and manufacturing plants. With the wide range of applications of our products, TCPCL can cater to customers across wide spectrum of chemical Industries which ensures a sustainable business model. Diversified product portfolio has helped accelerate our growth. We recently got listed on NSE/BSE on 29 July 2021, out of our net IPO proceeds of Rs 2,072.81 million, Rs 396.85 million have been utilized as on 30 September 2021. The capacity expansion is underway at our Dahej SEZ manufacturing plant and at our R&D facility at Vadodara. 

 

Result PDF

default
Tatva Chintan Pharma Chem Ltd.'s price crossed above SMA50 today
Recommended
More from Tatva Chintan Pharma Chem Ltd.